Dr. Lal PathLabs expands genomics capabilities with Illumina's NovaSeq X Series

25 Jun 2025 Evaluate

Dr. Lal PathLabs has expanded its genomics capabilities by adding Illumina’s NovaSeq X Series to its dedicated genomics division, Genevolve. With the integration of Illumina’s latest technology, the company can now deliver faster and more accurate genomic research insights. 

The NovaSeq X system features Illumina’s cutting-edge XLEAP-SBS chemistry, offering unmatched throughput, accuracy, and sustainability. The NovaSeq X Plus can generate more than 20,000 whole genomes per year, more than double the throughput of Illumina’s previous sequencers. Its unprecedented speed, scale, and accuracy push the limits of what’s possible in genetic sequencing. And its powerful technology allows users to unlock previously unimaginable discoveries and advancements.

Launched in 2019, Genevolve has swiftly emerged as a DNA-based center of excellence. The addition of Illumina products further strengthens Genevolve’s position as a pioneer in next-generation sequencing (NGS), enabling the company to deliver actionable, AI-powered insights with greater speed and sensitivity.

Dr. Lal Pathlabs is a provider of diagnostic and related healthcare tests and services in India.

Dr. Lal Pathlabs Share Price

3025.95 -28.50 (-0.93%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Apollo Hospital Ent. 7189.25
Max Healthcare Inst 1097.95
Narayana Hrudayalay 1916.45
Aster DM Healthcare 635.10
Global Health 1163.75
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×